Verge Genomics: the address we list now redirects elsewhere · last checked 29 Oct 2026
Verge Genomics
vBx-1.0 predicts brain activity, therapy response, and side effects from a routine blood draw, for precision neurology trials.
For CNS teams, vBx-1.0 is the most narrowly targeted model we have reviewed, and unusually for this category it ships with a quantified trial-design number: 52% to 69% responder enrichment and 43% fewer patients at fixed power in Parkinson's. If you are designing a Parkinson's or Alzheimer's study and enrollment cost is the binding constraint, that arithmetic alone justifies a conversation with the Verge team. Recursion and Insilico Medicine stay broader and more chemistry-centric; Verge is
Verdict generatedLast checked 6d ago · cite: rightaichoice.com/tools/verge-genomics
- Pharma sponsors designing Parkinson's or Alzheimer's trials who need patient enrichment
- Neurology research groups wanting human-validated CNS targets
- CNS biotechs that need biomarker identification before committing to a trial
- Trial planners who need a quantified enrollment-reduction case for leadership
- Any program outside central nervous system indications
- Research outside neurology, such as oncology or immunology
- Programs needing the 43% enrollment result extrapolated beyond Parkinson's without further evidence
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Verge Labs if your program is outside the central nervous system — oncology, immunology, or metabolic disease — because the model's 12,000-brain training substrate says nothing about those tissues.
Expect a data-sharing agreement alongside the commercial one: vBx-1.0 predictions are strongest on cohorts comparable to Verge's 6,000 paired patients, and reconciling your own sample and clinical data against that
Verge sells through a partnership and data-sharing agreement, so the cost comparison is not a subscription line item but a per-program deal weighed against what a failed CNS trial costs. For a sponsor whose Parkinson's study would otherwise enrol 43% more patients at fixed power, the platform has to clear that bar. Recursion and Insilico Medicine are the broader, chemistry-centric comparators.
In short
Verge Genomics — vBx-1.0 predicts brain activity, therapy response, and side effects from a routine blood draw, for precision neurology trials. Best for Pharma sponsors designing Parkinson's or Alzheimer's trials who need patient enrichment, Neurology research groups wanting human-validated CNS targets, CNS biotechs that need biomarker identification before committing to a trial. Pricing is on request (custom quotes).
No head-to-head comparison for Verge Genomics yet — the alternatives below are the closest matches we list.
What is Verge Genomics?
Verge Genomics — vBx-1.0 predicts brain activity, therapy response, and side effects from a routine blood draw, for precision neurology trials. Best for Pharma sponsors designing Parkinson's or Alzheimer's trials who need patient enrichment, Neurology research groups wanting human-validated CNS targets, CNS biotechs that need biomarker identification before committing to a trial. Pricing is on request (custom quotes).
Verge Labs builds foundation models for neurological disease that reason at the level of the individual patient. The substrate is human brain tissue: deep molecular profiling on 12,000+ brains across 6,000 patients with paired proteomic, genomic, and clinical data, plus a physical inventory of 900+ frozen brain tissue samples spanning the major neurodegenerative diseases. The flagship model, vBx-1.0, launched June 16, 2026 and is described as a virtual biopsy of the brain — a reconstruction of what's happening inside a patient's brain generated from a routine blood draw. The model predicts brain activity, therapy response, and side effects, and Verge reports up to 3x greater accuracy than previous state-of-the-art models on those tasks. The commercially legible output is trial design. Enriching a Parkinson's trial for L-DOPA responders with vBx-1.0 lifts the responder fraction from 52% to 69%, which cuts required enrollment by 43% at fixed statistical power. The platform spans target discovery, target characterization, biomarker identification, and patient stratification. Verge reports 280+ novel drug targets surfaced, an 83% preclinical validation rate, two AI-discovered drugs that have reached clinical candidates, and $1.6B in partnerships with top-20 pharma. A published vBx-1.0 technical report is available for scientific diligence. It's built for sponsors and researchers in Parkinson's, Alzheimer's, ALS, and frontotemporal dementia who need human-validated targets or patient enrichment before funding an expensive study. Verge is explicit that it starts with the brain; programs outside CNS have no training data behind them. Against broadly chemistry-centric discovery platforms, the differentiator is depth in one organ system instead of breadth.
Key features
- vBx-1.0 virtual biopsy model generating brain-state predictions from a routine blood draw
- Predicts brain activity, therapy response, and side effects in neurology patients
- Vendor-reported up to 3x greater accuracy than previous state-of-the-art models
- Trained on deep molecular profiling of 12,000+ brains across 6,000 patients
- Paired proteomic, genomic, and clinical data from the same patients
- Physical inventory of 900+ frozen brain tissue samples across major neurodegenerative diseases
- Target discovery run against proprietary human brain data
- Target characterization with a vendor-reported 83% preclinical validation rate
- Biomarker identification for clinical trial design
- Patient stratification and trial enrichment
- Lifts L-DOPA responder fraction from 52% to 69% in Parkinson's enrichment
- Reduces required Parkinson's trial enrollment by 43% at fixed statistical power
- 280+ novel drug targets surfaced across programs
- Two AI-discovered drugs that have reached clinical candidates
- Published vBx-1.0 technical report available for scientific diligence
Behind the verdict
Most AI drug-discovery platforms sell breadth: every target, every tissue, every modality. Verge Labs went the other direction and built a dataset that's genuinely hard to copy — over a decade of multi-modal molecular profiling from human brains, with paired proteomic, genomic, and clinical data from the same patients. That's the real moat, not the model architecture. Where it earns a meeting: you're a sponsor or CNS biotech stuck on enrollment math. The vBx-1.0 technical report gives you a specific number to argue with — enriching a Parkinson's trial for L-DOPA responders moves the responder fraction from 52% to 69% and cuts required patients by 43% at fixed power. Take that to your biostatistician before you take it to your CFO. Where we'd pass: any program outside neurology. If you're working in oncology, immunology, or metabolic disease, there is no training data behind you here, and the platform won't pretend otherwise. Likewise if you need chemistry-first generative design — Verge is a target-and-patient platform, not a molecule generator. Comparative placement matters. Recursion and Insilico Medicine cast a wider net across biology and chemistry. Verge is the specialist bet that CNS is different enough to need its own ground truth. That's defensible, but it also means fewer programs fit through the door. Real-world caveats. The headline accuracy and enrollment figures are vendor-reported from a June 16, 2026 technical report — STAT News covered the model, but independent replication is still the thing to ask about in diligence. The 43% result is demonstrated in Parkinson's; don't extrapolate it to ALS or FTD without asking for the underlying data. And the economics are enterprise-shaped: this is a partnership conversation, not a credit-card signup.
Models under the hood
as of 2026-10-22
Limitations
- The platform is built on neuroscience-specific data — molecular profiling of 12,000+ brains across 6,000 patients — and is positioned for CNS drug development rather than general-purpose use.
- Performance figures such as up to 3x greater accuracy than prior state-of-the-art models, the 52% to 69% L-DOPA responder-fraction lift, and the 43% reduction in required Parkinson's trial enrollment are the vendor's own numbers from its June 16, 2026 technical report, so they should be treated as vendor-reported rather than independently audited.
- The cited trial-enrichment result is shown for Parkinson's enrichment specifically.
as of 2026-10-19
Researching Verge Genomics? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Is Verge Genomics still active?
Verge Genomics: the address we list now redirects elsewhere · last checked 29 Oct 2026.
Viability score
How well maintained and how widely used is Verge Genomics? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →What do users say about Verge Genomics?
What people actually say about Verge Genomics — is it worth it?
We scanned public community sources for Verge Genomics on Sep 9, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Only 2 of the posts we fetched could be positively tied to Verge Genomics. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.
How we verified this
Every listed fact about Verge Genomics— pricing, features, links, status — is re-read from the vendor's own pages by our verification pipeline and each change is logged with a date; the last pass ran on 24 Oct 2026. Pages mix model-assisted synthesis with human review; see how we verify.
Verification history
We have re-verified Verge Genomics 21 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — changed description, summary, our verdict
- — changed limitations
- — changed who should skip it, setup time, pricing fit, limitations, hidden costs, description, summary, features, our verdict, who it suits, models, switching out, switching in, SSL certificate
- — changed our verdict, who it suits, description, features, who should skip it, summary
- — changed models, limitations
- — changed features, summary, limitations, who it suits, switching in, hidden costs, switching out, our verdict, who should skip it, pricing fit, setup time, description, use cases
Showing the 6 most recent of 21 verification passes.
Free to cite with attribution — this page re-verifies continuously.
How much does Verge Genomics cost in 2026?
Verge Genomics: Pricing is on request (custom quotes). Pricing last verified 24 Oct 2026.
Where the pricing makes sense
The company stage and team size where Verge Genomics's pricing actually pencils out — and where peers do it cheaper.
Verge sells through a partnership and data-sharing agreement, so the cost comparison is not a subscription line item but a per-program deal weighed against what a failed CNS trial costs. For a sponsor whose Parkinson's study would otherwise enrol 43% more patients at fixed power, the platform has to clear that bar. Recursion and Insilico Medicine are the broader, chemistry-centric comparators.
Who should pick Verge Genomics?
Pick Verge Genomics if you are Pharma sponsors designing Parkinson's or Alzheimer's trials who need patient enrichment, Neurology research groups wanting human-validated CNS targets, CNS biotechs that need biomarker identification before committing to a trial, Trial planners who need a quantified enrollment-reduction case for leadership.
Look elsewhere if you are Any program outside central nervous system indications, Research outside neurology, such as oncology or immunology, Programs needing the 43% enrollment result extrapolated beyond Parkinson's without further evidence.
Skip it if Skip Verge Labs if your program is outside the central nervous system — oncology, immunology, or metabolic disease — because the model's 12,000-brain training substrate says nothing about those tissues.
GeneratedReal-world workflow fit
Concrete scenarios for the personas Verge Genomics actually fits — and what changes day-one when you adopt it.
You are scoping a Phase 2 Parkinson's study and the CRO's enrollment quote is the number your CFO keeps pushing back on. You contract with Verge to run vBx-1.0 enrichment on your screening strategy for L-DOPA responders.
Outcome: Verge's reported 52%-to-69% responder lift translates into 43% fewer patients required at fixed statistical power, which becomes the enrollment case you take to the portfolio committee.
You have a list of candidate CNS targets from genetics and want to know which ones have human tissue evidence behind them before committing medicinal chemistry spend. You run the candidates against Verge's proprietary brain data.
Outcome: You get target characterization against human proteomic and genomic data with a vendor-reported 83% preclinical validation rate, letting you deprioritize targets with no human signal.
You need biomarkers that separate fast and slow progressors before locking a cohort. You bring paired multi-omic and clinical questions to the Verge platform rather than designing the study around convenience samples.
Outcome: You leave with biomarker candidates drawn from the 900+ frozen tissue inventory and 6,000 paired patients, and a stratification plan that reflects predicted therapy response.
Use cases
- Enrich a Parkinson's trial for L-DOPA responders to cut required enrollment by 43% at fixed power
- Identify novel drug targets for ALS from proprietary human brain genomic and proteomic data
- Stratify Alzheimer's patients by predicted therapy response before committing to a trial
- Characterize a CNS target against human tissue data to raise the odds of preclinical validation
- Find biomarkers for a frontotemporal dementia program using paired multi-omic and clinical data
- Prioritize which of several candidate CNS targets to drug based on predicted patient response
- Predict on-target and off-target side effects for a neurology candidate from a blood draw
Setup time & first value
How long it actually takes to get something useful out of Verge Genomics — broken out by persona, not the marketing-page minute.
Expect weeks rather than days to first value: a partnership and data-sharing agreement precedes any modeling, and your cohort's sample and clinical data then have to be mapped onto Verge's schema. Sponsors who already hold paired genomic and clinical trial data move fastest.
Switching to or from Verge Genomics
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From a CRO-led stratification heuristic: bring your existing responder definitions and patient cohort data to Verge so vBx-1.0 predictions can be benchmarked against the 52%-to-69% L-DOPA enrichment result.
Resources & guides
Tutorials & Learning
YouTube returned 6 videos for “Verge Genomics”, and we withheld 5: 5 did not mention Verge Genomics. Showing the 1 we can prove is about Verge Genomics.
Official links
What are the best Verge Genomics alternatives?
The closest alternatives to Verge Genomics we list are WhiteLab Genomics, Cellino and Atlas Discovery. Ranked by direct product-type match, not category overlap.
| Alternative | Pricing | Starts at | Last verified |
|---|---|---|---|
| WhiteLab Genomics | Contact Sales | Custom pricing | — |
| Cellino | Contact Sales | Custom pricing | — |
| Atlas Discovery | Contact Sales | Custom pricing | — |
Alternatives to Verge Genomics
View all
WhiteLab Genomics
AI platform that predicts and optimizes molecular constructs for gene and RNA therapy before synthesis
Cellino
Cellino's AI-guided optical bioprocessing platform brings patient-specific cell therapy manufacturing to the hospital.
Atlas Discovery
AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response
Tools that pair well with Verge Genomics
Common stack mates teams adopt alongside Verge Genomics, with the specific reason each pairing earns its keep.
WhiteLab Genomics
AI platform that predicts and optimizes molecular constructs for gene and RNA therapy before synthesis
Cellino
Cellino's AI-guided optical bioprocessing platform brings patient-specific cell therapy manufacturing to the hospital.
Atlas Discovery
AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response
Categories
Best-of guides
Topics
Used Verge Genomics? Help shape our editorial sentiment research.